





Major R&D Pipeline: 3 ADCs


As of January 2021



Phase 1		Phase 2	Phase 3	Submitted
(JP/US) NSCLC, TNBC TROPION-PanTumor01	(US/EU/Asia) HER2+ BC 2L~/1L DESTINY-Breast07	(US/EU/Asia) TNBC (durvalumab combo) BEGONIA	(JP/US/EU/Asia)HER2+ BC 3L DESTINY-Breast02	
(JP/US) NSCLC (w/o actionable mutation, pembrolizumab combo) TROPION-Lung02	(US/EU/Asia) HER2 low BC chemo naïve/ post chemo DESTINY-Breast08	(US/EU) HER2+ GC 2L DESTINY-Gastric02	(JP/US/EU/Asia) HER2+ BC 2L DESTINY-Breast03	
(JP/US) NSCLC (w/o (actionable mutation, durvalumab combo) TROPION-Lung04	(US/EU/Asia) HER2+ GC combo, 2L~/1L DESTINY-Gastric03	(JP/US/EU)HER2+/mutated NSCLC DESTINY-Lung01 	(JP/US/EU/Asia) HER2 low BC post chemo DESTINY-Breast04	
(JP/US/EU/Asia) NSCLC	(EU/Asia)HER2+ NSCLC (durvalumab combo) DESTINY-Lung03	(JP/US/EU)HER2+/mutated NSCLC DESTINY-Lung02	(JP/US/EU/Asia) HER2+ BC post neoadjuvant DESTINY-Breast05	
(JP/US)EGFRm NSCLC (osimertinib combo)	(US/EU) BC, bladder (nivolumab combo)	(US/EU/Asia) NSCLC(durvalumab combo) HUDSON	(JP/US/EU/Asia) HER2 low BC chemo naïve DESTINY-Breast06	
(JP/US) HER3+ BC	(US/EU) BC, NSCLC (pembrolizumab combo)	(JP/US/EU) HER2+ CRC DESTINY-CRC01	(JP/US/EU/Asia) HER2+ GC 2L DESTINY-Gastric04	
		(US/EU/Asia) HER2 mutated tumor DESTINY-PanTumor01	(JP/US/EU/Asia) NSCLC(w/o actionable mutation) TROPION-Lung01	
		(US/EU/Asia) HER2 expressing tumor DESTINY-PanTumor02		
		(JP/US/EU/Asia) NSCLC (w actionable mutation) TROPION-Lung05		
		(JP/US) EGFRm NSCLC HERTHENA-Lung01		
		(JP/US/EU) HER3+ CRC		

-  DS-8201 HER2-directed ADC
-  DS-1062 TROP2-directed ADC
-  U3-1402 HER3-directed ADC

BC: breast cancer, CRC: colorectal cancer, GC: gastric cancer, NSCLC: non-small cell lung cancer, TNBC: triple negative breast cancer

 : Breakthrough Designation (US)

Major R&D Pipeline: Alpha

As of January 2021



Phase 1		Phase 2		Phase 3		Submitted	
DS-7300 (JP/US) B7-H3-directed ADC Solid tumors	DS-3201 (JP/US) EZH1/2 inhibitor Non-Hodgkin's lymphomas	DS-3201 (JP) EZH1/2 inhibitor ATL/L		Quizartinib (JP/US/EU/Asia) FLT3 inhibitor 1L AML QuANTUM-First		DS-1647 (G47Δ) (JP) Oncolytic HSV-1 Malignant glioma IIS	
DS-6157 (JP/US) GPR20-directed ADC GIST	DS-3201 (US) EZH1/2 inhibitor AML, ALL	DS-3201 (JP/US/EU/Asia) EZH1/2 inhibitor PTCL		Pexidartinib (JP/Asia) CSF-1/KIT/FLT3 inhibitor Tenosynovial giant cell tumor		Edoxaban (JP) FXa inhibitor AF in the very elderly	
DS-6000 (US) CDH6-directed ADC Renal cell carcinoma, ovarian cancer	PLX2853 (US) BET inhibitor AML	DS-1001 (JP) Mutant IDH1 inhibitor Glioma		Mirogabalin (JP/Asia) α ₂ δ Ligands Central neuropathic pain		Prasugrel (JP) ADP receptor inhibitor Ischemic stroke	
DS-1055 (JP/US) Anti-GARP antibody Solid tumors	PLX2853 (US) BET inhibitor Solid tumor	DS-5141 (JP) ENA oligonucleotide DMD		Esaxerenone (JP) MR blocker Diabetic nephropathy		VN-0107/MEDI3250 (JP) Live attenuated influenza vaccine nasal spray	
DS-2741 (JP) Anti-Orai1 antibody Atopic dermatitis	PLX2853 (US) BET inhibitor Gynecologic neoplasms, ovarian cancer	DS-1211 (US) TNAP inhibitor Pseudoxanthoma elasticum		VN-0102/JVC-001 (JP) Measles mumps rubella combined vaccine			
	PLX2853 (US) BET inhibitor Prostate cancer						

Oncology

Specialty medicine

Vaccine

AF: atrial fibrillation, ALL: acute lymphocytic leukemia, AML: acute myeloid leukemia, ATL/L: adult T-cell leukemia/lymphoma, DMD: Duchenne muscular dystrophy, GIST: gastrointestinal stromal tumor, IIS: investigator-initiated study, NSCLC: non-small cell lung cancer, PTCL: peripheral T-cell lymphoma

□: project in oncology that is planned to be submitted for approval based on the results of phase 2 trials

☀: SAKIGAKE Designation (JP) 🌺: Orphan drug designation (JP/US/EU)